Psyence Biomedical Ltd.
PBM
$1.70
$0.127.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 872.80K | 825.40K | 825.40K | 890.50K |
| Depreciation & Amortization | 1.30K | 1.30K | 1.20K | 1.20K | 1.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51M | 1.21M | 864.90K | 864.90K | 1.16M |
| Operating Income | -1.51M | -1.21M | -864.90K | -864.90K | -1.16M |
| Income Before Tax | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -753.30K | -996.40K | -974.40K | -974.40K | 141.50K |
| EBIT | -1.51M | -1.21M | -864.90K | -864.90K | -1.16M |
| EBITDA | -1.51M | -1.21M | -863.70K | -863.70K | -1.16M |
| EPS Basic | -0.51 | -0.94 | -2.73 | -2.73 | 4.07 |
| Normalized Basic EPS | -0.63 | -0.71 | -1.40 | -1.40 | -26.00 |
| EPS Diluted | -0.51 | -0.94 | -2.73 | -2.73 | 4.07 |
| Normalized Diluted EPS | -0.63 | -0.71 | -1.40 | -1.40 | -25.99 |
| Average Basic Shares Outstanding | 1.48M | 1.06M | 357.10K | 357.10K | 34.70K |
| Average Diluted Shares Outstanding | 1.48M | 1.06M | 357.10K | 357.10K | 34.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |